Focus: Otsuka is a Japan-based specialty pharma company headquartered in Tokushima with a focused portfolio in small molecules across neurology, psychiatry, nephrology, and oncology. The company derives 84% of revenue from REXULTI, indicating a highly concentrated, single-asset-dependent business model.
Profile data last refreshed 9h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Otsuka to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Otsuka
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Otsuka's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Otsuka's cash engine, representing 84% of company revenue; sustained by multiple indication approvals and extension of exclusivity into early 2030s.
Second-largest franchise addressing rare kidney disease; faces patent cliff by 2030 but multiple Phase 2–4 tolvaptan programs may sustain franchise.
Long-acting depot formulation extending classic aripiprazole lifecycle; smaller revenue base but strategically important for treatment adherence in serious mental illness.
Branded hyponatremia indication; overlaps with JYNARQUE but addresses distinct patient populations; patent cliff risk shared with JYNARQUE.
Core franchise entering generic competition by 2027; immediate patent cliff driver and first major revenue erosion event on company horizon.
45 discontinued, 59 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
No recent FDA warnings or WARN Act filings detected, but single active supply shortage (Sterile Water Irrigant) is minor operational risk.
+23 more products